In AD patients with ApoE4, the higher the tau level in cerebrospinal fluid (CSF), the worse the plasticity of long-term potentiation- (LTP-) like cortical, and the faster the disease progression [30]. This evidence concerns the gene MAPT and Alzheimer disease.